Investment
Features
FeesSafety
Academy
More
Pluang+

Tuttle Capital launches PCPC ETF tracking P&C insurers ranked by underwriting profit, not size.

Market News
15 Sep 2026
Newsfile Corp
View Source
Bullish
Tuttle Capital launches PCPC ETF tracking P&C insurers ranked by underwriting profit, not size.

Tuttle Capital Management has launched the Porter & Company Property & Casualty Index ETF (PCPC), which tracks an index ranking U.S. property and casualty insurers by underwriting profit, measured by combined ratio, rather than market capitalization. The ETF invests in up to 20 insurers with strong underwriting discipline, weighting them inversely to their combined ratio to favor the most profitable underwriters. This approach offers investors a unique way to gain exposure to insurance companies that excel in underwriting, potentially serving as an alternative or complement to traditional bond investments. The fund has a 0.65% expense ratio and will trade on Cboe BZX under ticker PCPC.

The launch of the Porter & Company Property & Casualty Index ETF (PCPC) provides a new approach to investing in U.S. property and casualty insurers. For readers following the Financials sector, here is Pluang's market snapshot as of Sep 15, 2026 19:02 WIB: out of 74 priced US Financials stocks, 21 rose and 48 fell. Notable movers include SAN (Banco Santander SA) at USD 14.63 with a -0.75% change, ING (ING Groep NV) at USD 36.71 with a -0.68% change, and AFRM (Affirm Holdings Inc) at USD 72.90 with a -0.65% change.

More News

Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma A/S regained full control of its TransCon technology for metabolic diseases from Novo Nordisk, allowing it to independently develop and sell treatments, including for obesity. The company also authorized a $400 million share repurchas...

Market News
Bullish
4 hours ago
Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.

Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.

Deutsche Bank upgraded AstraZeneca's stock rating from Sell to Hold following mixed results from its drug trials. The lung disease drug tozorakimab showed strong Phase III results and received FDA priority review, signaling potential future growth. H...

Analyst Insights
Neutral
4 hours ago
Alphabet shares seen with 50% upside as its Cloud growth outpaces cheap valuation

Alphabet shares seen with 50% upside as its Cloud growth outpaces cheap valuation

Alphabet's stock is undervalued with a 50% upside potential, trading at a low P/E of 17 despite rapid growth, especially in its Cloud segment which grew 82% year-over-year with a $514 billion backlog. The company reported strong Q2 2026 earnings, bea...

Analyst Insights
Bullish
4 hours ago
ASML shares drop 14% but remain a strong buy with robust AI-driven growth and a $45B order backlog.

ASML shares drop 14% but remain a strong buy with robust AI-driven growth and a $45B order backlog.

ASML's stock fell over 14% recently, yet it remains a strong buy due to its monopoly on EUV lithography machines essential for advanced chip manufacturing. The company reported a 21.3% revenue increase in Q2 2026 and raised its full-year guidance, su...

Analyst Insights
Bullish
4 hours ago
Shengfeng reports 18.4% revenue growth in H1 2026, driven by expanded logistics services.

Shengfeng reports 18.4% revenue growth in H1 2026, driven by expanded logistics services.

Shengfeng Development Limited announced an 18.4% increase in revenue to $311.8 million for the first half of 2026, mainly due to growth in transportation services and expanded client partnerships. Gross profit rose 11.3%, though gross margin slightly...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App